Drug Trial Radar · NCT07926217
High-Dose Versus Standard-Dose Influenza Vaccine in Patients With Hematologic Malignancies Receiving B-Cell-Depleting Therapy
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Nov 2, 2026
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Sung-Han KimAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized trial will compare the immune responses to high-dose and standard-dose influenza vaccines in 60 adults with blood cancers (hematologic malignancies) who have received B-cell-depleting therapy. Participants will be assigned by chance, in a 1:1 ratio, to receive one of the two vaccines. Antibody and T-cell responses will be measured before and after vaccination. Participants and their treating clinicians will know which vaccine is given. Laboratory staff who measure and interpret the immune responses will not know which vaccine each participant received until the laboratory results are finalized.
Conditions
- Hematologic Malignancy
- Influenza
Interventions
High-dose inactivated influenza vaccineBiological
Trivalent inactivated influenza vaccine containing 60 micrograms of hemagglutinin per strain, administered as a single intramuscular injection on Day 0. It contains four times the hemagglutinin antigen per strain of the standard-dose vaccine.
Standard-dose inactivated influenza vaccineBiological
Trivalent inactivated influenza vaccine containing 15 micrograms of hemagglutinin per strain, administered as a single intramuscular injection on Day 0. It is the comparator for the high-dose vaccine.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Seroconversion Rate at Day 28 After Influenza VaccinationTime frame: Day 28 (±7 days) after vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Asan Medical Center
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.